Common Stock, par value $0.01 per share
- Symbol
- RGEN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Repligen Corporation
RGENNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2026, Karen A. Dawes notified Repligen Corporation (“Repligen”) that she will be retiring from the Repligen Board of Directors (the “Board”) after over twenty years of distinguished service to Repligen, effective as of September 30, 2026. Ms.…
Company context
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesNov 6, 2026
- 10-Q filingOct 30, 2026
- Unregistered Sales of Equity Securities · Other EventsOct 30, 2026
- Results of Operations and Financial ConditionOct 27, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding REPLIGEN CORPOct 7, 2026
Registered securities in this filing
REPLIGEN CORP · 8-K · Filed 2026-09-15
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 10, 2026, Karen A. Dawes notified Repligen Corporation (“Repligen”) that she will be retiring from the Repligen Board of Directors (the “Board”) after over twenty years of distinguished service to Repligen, effective as of September 30, 2026.
Ms. Dawes commented, “It has been a privilege and an honor to serve on Repligen's Board and to contribute to the Company's transformation over the years. With a successful CEO transition complete, I believe now is the right time for my retirement. I am proud of what we have accomplished together and leave knowing Repligen is supported by an outstanding leadership team and Board. I am confident the Company is well-positioned for continued success and its next phase of growth.”
Ms. Dawes’s decision to retire from the Board is not the result of any disagreement with Repligen with respect to Repligen’s operations, policies or procedures.